GLAFENINE HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H17ClN2O4.ClH
Molecular Weight	409.263
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.OCC(O)COC(=O)C1=C(NC2=C3C=CC(Cl)=CC3=NC=C2)C=CC=C1

InChI

InChIKey=CEUMONXVSJOJIH-UHFFFAOYSA-N

InChI=1S/C19H17ClN2O4.ClH/c20-12-5-6-14-17(7-8-21-18(14)9-12)22-16-4-2-1-3-15(16)19(25)26-11-13(24)10-23;/h1-9,13,23-24H,10-11H2,(H,21,22);1H

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1675606
Curator's Comment: description was created based on several sources, including http://www.thepharmaletter.com/article/glafenine-french-temp-withdrawal

Glafenine is a non-steroidal anti-inflammatory drug (NSAID). Glafenine was withdrawn due to the risk of anaphylaxis and acute kidney failure.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Spasm 18 Sources: http://www.ncbi.nlm.nih.gov/pubmed/5421810	Primary		Withdrawn	Unknown Approved Use Unknown
Pain 614 Sources: http://www.ncbi.nlm.nih.gov/pubmed/4141989	Secondary		Withdrawn	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Synthesis and analgesic activities of some (4-substituted phenyl-1-piperazinyl)alkyl 2-aminobenzoates and 2-aminonicotinates.	1979 May	458805
[13 cases of drug-induced calculi].	1988	2903714
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
LC-MS/MS systematic toxicological analysis: comparison of MS/MS spectra obtained with different instruments and settings.	2005 Apr	15766737
Synthesis of novel 4-substituted-7-trifluoromethylquinoline derivatives with nitric oxide releasing properties and their evaluation as analgesic and anti-inflammatory agents.	2005 Oct 15	16002298
A novel flow cytometric high throughput assay for a systematic study on molecular mechanisms underlying T cell receptor-mediated integrin activation.	2009 Jun 25	19557182

Patents

Sample Use Guides

In Vivo Use Guide

200-400 mg, 3-4 times per day

Route of Administration: Oral

In Vitro Use Guide

human aortic smooth muscle cells (haSMCs) and human endothelial cells (ECs) were seeded in tissue culture flasks. The cells were treated for 4 days with glafenine hydrochloride (10 uM, 50 uM, 100 uM). Half of the treated groups were incubated again with glafenine hydrochloride, the other half received medium free of glafenine hydrochloride every 4 days until day 20.

Name

Type

Language

GLAFENINE HYDROCHLORIDE

Common Name

English

GLAFENIN HYDROCHLORIDE

Common Name

English

Glafenine hydrochloride [WHO-DD]

Common Name

English

(±)-GLAFENINE HYDROCHLORIDE

Common Name

English

BENZOIC ACID, 2-((7-CHLORO-4-QUINOLINYL)AMINO)-, 2,3-DIHYDROXYPROPYL ESTER, HYDROCHLORIDE (1:1)

Common Name

English

Code System Code Type Description

FDA UNII

MS23T96ZZP